Table 5.
Sequence and type of CpG oligodeoxynucleotides (CpG-ODN) used in pre-clinical studies ( Table 2 ) and clinical trials ( Table 3 ).
| CpG-ODN name or study | Species used | Sequence | CpG-ODN type/structure |
|---|---|---|---|
| A-Class | |||
| G10 (156) | Human | 5′-GGGGGGGGGGGACGATCGTCGGGGGGGGGG-3′ | A-class |
| CpG-ODN 2216 | Human | 5′-GGGGGACGATCGTCGGGGGG-3′ | A-class |
| Fanucchi et al. (101) | Mouse | 5′TGACTGTGAACGTTCGAGATGA-3′ | A-class |
| Sabatel et al., 2017 (76) | Mouse | 5′-TCCATGACGTTCCTGATGCT-3′ | A-class |
| B-Class | |||
| 1018 ISS (CpG-ODN 1018) | Human and mouse | 5′-TGACTGTGAACGTTCGAGATGA-3′ | B-class |
| CpG-ODN 7909 = CpG-ODN 2006 | Human | 5′- TCGTCGTTTTGTCGTTTTGTCGTT -3′ | B-class |
| Kline et al. (97), Jain et al. (100) | Mouse | 5′-TCCATGACGTTCCTGACGTT-3′ | B-class |
| Jahn-Schmid et al. (86) | Mouse | 5′-ATCGACTCTCGAGCGTTCTC-3′ | B-class |
| Sur et al., 1999 (98) | Mouse | 5′-GCTAGACGTTAGCGT-3′ | B-class |
| Peng et al. (99) | Mouse | 5′-TCCATGACGTTCCTGACGTT-3′ | B-class |
| CpG-ODN 1826 | Mouse | 5′-TCCATGACGTTCCTGACGTT-3′ | B-class |
| CpG-ODN BL07S | Mouse | 5′-GCGTCGGTTTCGGTGCTCAC-3′ | B-class |
| CpG-ODN 1668 (79) | Mouse | 5′-TCCATGACGTTCCTGATGCT-3′ | B-class |
| Chang et al. (104) | Mouse | 5′-TCCATGACGTTCCTGACGTT-3′ | B-class |
| C-Class | |||
| IMO-2125 (Tilsotolimod) | Human | 5′-TCG*AACG*TTCG*-X-G*CTTG*CAAG*CT-3′ | C-class |
| SD-101 | Human | Not described. | C-class |
| CpG-ODN 2395 | Mouse | 5′-TCGTCGTTTTCGGCGCGCGCCG-3′ | C-class |
| Others | |||
| MGN1703 (Lefitolimod) | Human | CTAGGGGTTACCACCTTCATTGGAAAACGTTCTTCGGGGCGTTCTTAGGTGGTAACCC by dimer-circularization | Double-stem loop immunomodulators (dSLIM) (157, 158) |
| Fonseca et al. (105) | Mouse | Not described. | Not described. |